Protocol | In Vitro | AGEs-induced beta cell necrosis is completely abrogated by adding Pioglitazone to the AGEs culture medium. Furthermore Pioglitazone completely prevented any AGEs-induced increment in caspase-3 activation, thereby restoring caspase-3 activity to the same levels as the control cells. As expected AG is able to counteract AGEs-induced impaired viability. |
---|
In Vivo | The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are significantly reduced to a similar degree after 30 mg/kg Pioglitazone. Moreover, the expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice are unchanged after 10 mg/kg Pioglitazone but are decreased after 30 mg/kg Pioglitazone. Thus, Pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added |
Mass (the weight of a compound) |
Mother liquor concentration |
1mg | 5mg | 10mg | 20mg |
1mM | 2.5452 mL | 12.7259 mL | 25.4518 mL | 50.9035 mL |
---|
5mM | 0.5090 mL | 2.5452 mL | 5.0904 mL | 10.1807 mL |
---|
10mM | 0.2545 mL | 1.2726 mL | 2.5452 mL | 5.0904 mL |
---|
20mM | 0.1273 mL | 0.6363 mL | 1.2726 mL | 2.5452 mL |
Quality Control Documentation
|
|